Are you sure?

J&J's Prezista wins conditional marketing approval in Europe

Johnson & Johnson's Prezista, a treatment for people infected with the AIDS virus, won conditional approval to be marketed in the European Union.

The status means that the drug can be marketed in the union's 27 member countries, although additional data will need to be filed each year until full approval is granted, the company said today in a statement on Business Wire. (Bloomberg)